Abstract
Recombinant adenoviral vectors have served as one of the most efficient gene delivery vehicles in vivo thus far. Multiply attenuated or completely gutless adenoviral vectors have been developed to achieve long-term gene expression in animal models by overcoming cellular immunity against de novo synthesized adenoviral proteins. However, since adenovirus lacks native integration machinery, the goal of gene therapy obtaining permanent expression cannot be realized with current adenoviral vector systems. Recent studies have shown that replication-incompetent adenoviral vectors randomly integrate into host chromosomes at frequencies of 0.001-1% of infected cells. To improve the integration frequencies of adenoviral vectors, a variety of hybrid vectors combining the highly efficient DNA delivery of adenovirus with the integrating machinery of retroviruses, adeno-associated viruses, and transposons, have been emerging. These hybrid vectors have shown promise, at least in in vitro systems. Furthermore, a denoviral vectors have shown potential as gene targeting vectors. These developments should eventually lead to more effective gene therapy vectors that can transduce a myriad of cell types stably in vivo.
Keywords: Adenovirus, Integrating Vector, HOST CHROMOSOMES, Colony-forming units
Current Gene Therapy
Title: Adenovirus As An Integrating Vector
Volume: 2 Issue: 2
Author(s): K. Mitani and S. Kubo
Affiliation:
Keywords: Adenovirus, Integrating Vector, HOST CHROMOSOMES, Colony-forming units
Abstract: Recombinant adenoviral vectors have served as one of the most efficient gene delivery vehicles in vivo thus far. Multiply attenuated or completely gutless adenoviral vectors have been developed to achieve long-term gene expression in animal models by overcoming cellular immunity against de novo synthesized adenoviral proteins. However, since adenovirus lacks native integration machinery, the goal of gene therapy obtaining permanent expression cannot be realized with current adenoviral vector systems. Recent studies have shown that replication-incompetent adenoviral vectors randomly integrate into host chromosomes at frequencies of 0.001-1% of infected cells. To improve the integration frequencies of adenoviral vectors, a variety of hybrid vectors combining the highly efficient DNA delivery of adenovirus with the integrating machinery of retroviruses, adeno-associated viruses, and transposons, have been emerging. These hybrid vectors have shown promise, at least in in vitro systems. Furthermore, a denoviral vectors have shown potential as gene targeting vectors. These developments should eventually lead to more effective gene therapy vectors that can transduce a myriad of cell types stably in vivo.
Export Options
About this article
Cite this article as:
Mitani K. and Kubo S., Adenovirus As An Integrating Vector, Current Gene Therapy 2002; 2 (2) . https://dx.doi.org/10.2174/1566523024605591
DOI https://dx.doi.org/10.2174/1566523024605591 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Cancer Invasion and Metastasis: Discovering New Targets For Diagnosis and Therapeutics
Current Signal Transduction Therapy Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Will Antiangiogenic Agents be a Future for Mesothelioma Therapy?
Current Medicinal Chemistry Recent Advances in Oncogenic Roles of the TRPM7 Chanzyme
Current Medicinal Chemistry Feasibility of Targeting Glioblastoma Stem Cells: From Concept to Clinical Trials
Current Topics in Medicinal Chemistry Geniposide Attenuates Mitochondrial Dysfunction and Memory Deficits in APP/PS1 Transgenic Mice
Current Alzheimer Research Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Distinctive Cellular Roles for Novel Protein Kinase C Isoenzymes
Current Pharmaceutical Design Recent Clinical Experience with Oncolytic Viruses
Current Pharmaceutical Biotechnology Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Glutamate Receptor Agonists: Stereochemical Aspects
Current Topics in Medicinal Chemistry Receptor-Specific Peptides for Targeting of Liposomal, Polymeric, and Dendrimeric Nanoparticles in Cancer Diagnosis and Therapy
Current Molecular Imaging (Discontinued) Mesenchymal Cells in the Treatment of Spinal Cord Injury: Current & Future Perspectives
Current Stem Cell Research & Therapy The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Recent Patents on Imaging Nanoprobes for Brain Tumor Diagnosis and Therapy
Recent Patents on Biotechnology Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Current Signal Transduction Therapy